Eloxx Pharmaceuticals annual capital expenditures (capex)
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2021
2022
Eloxx Pharmaceuticals Capital Expenditures (CapEx) Growth & History (ELOX)
Eloxx Pharmaceuticals's capital expenditures (capex) was $66,000 for fiscal 2022.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | $66,000 | −$23,000 | −25.84% |
| 2021 | 2021-12-31 | $89,000 | — | — |
| 2019 | 2019-12-31 | $40,000 | −$195,000 | −82.98% |
| 2018 | 2018-12-31 | $235,000 | −$2,000 | −0.84% |
| 2017 · Dec 31 | 2017-12-31 | $237,000 | $201,000 | +558.33% |
| 2017 · Jun 30 | 2017-06-30 | $2,500 | $2,500 | — |
| 2016 · Dec 31 | 2016-12-31 | $36,000 | $26,000 | +260.00% |
| 2016 · Jun 30 | 2016-06-30 | $0 | −$122,641 | — |
| 2015 · Dec 31 | 2015-12-31 | $10,000 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $122,641 | $119,447 | +3739.73% |
| 2014 | 2014-06-30 | $3,194 | $1,913 | +149.34% |
| 2013 | 2013-06-30 | $1,281 | −$3,180 | −71.28% |
| 2012 | 2012-06-30 | $4,461 | $2,435 | +120.19% |
| 2011 | 2011-06-30 | $2,026 | $910 | +81.54% |
| 2010 | 2010-06-30 | $1,116 | — | — |
Eloxx Pharmaceuticals quarterly capital expenditures (capex)
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q3 2023 | 2023-09-30 | $0 | −$48,000 | — |
| Q2 2023 | 2023-06-30 | $0 | −$7,000 | — |
| Q1 2023 | 2023-03-31 | $0 | −$11,000 | — |
| Q4 2022 | 2022-12-31 | $0 | — | — |
| Q3 2022 | 2022-09-30 | $48,000 | — | — |
| Q2 2022 | 2022-06-30 | $7,000 | — | — |
| Q1 2022 | 2022-03-31 | $11,000 | — | — |
| Q4 2019 | 2019-12-31 | $0 | −$102,000 | — |
| Q3 2019 | 2019-09-30 | $24,000 | −$8,000 | −25.00% |
| Q2 2019 | 2019-06-30 | $0 | −$44,000 | — |
| Q1 2019 | 2019-03-31 | $16,000 | −$41,000 | −71.93% |
| Q4 2018 | 2018-12-31 | $102,000 | $20,000 | +24.39% |
| Q3 2018 | 2018-09-30 | $32,000 | −$27,000 | −45.76% |
| Q2 2018 | 2018-06-30 | $44,000 | $22,000 | +100.00% |
| Q1 2018 · Mar 31 | 2018-03-31 | $57,000 | −$17,000 | −22.97% |
| Q4 2017 | 2017-12-31 | $82,000 | — | — |
| Q1 2018 · Sep 30 | 2017-09-30 | $59,000 | — | — |
| Q4 2017 · Jun 30 | 2017-06-30 | $22,000 | $22,000 | — |
| Q1 2017 · Mar 31 | 2017-03-31 | $74,000 | $74,000 | — |
| Q4 2016 | 2016-06-30 | $0 | −$5,383 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | $0 | −$6,213 | — |
| Q4 2015 | 2015-12-31 | $0 | −$36,718 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | $0 | −$74,327 | — |
| Q4 2015 | 2015-06-30 | $5,383 | $2,189 | +68.53% |
| Q3 2015 | 2015-03-31 | $6,213 | $6,213 | — |
| Q2 2015 | 2014-12-31 | $36,718 | $36,718 | — |
| Q1 2015 | 2014-09-30 | $74,327 | $74,327 | — |
| Q4 2014 | 2014-06-30 | $3,194 | $3,194 | — |
| Q3 2014 | 2014-03-31 | $0 | $0 | — |
| Q2 2014 | 2013-12-31 | $0 | $0 | — |
| Q1 2014 | 2013-09-30 | $0 | −$1,281 | — |
| Q4 2013 | 2013-06-30 | $0 | −$223,468 | — |
| Q3 2013 | 2013-03-31 | $0 | $0 | — |
| Q2 2013 | 2012-12-31 | $0 | −$99,090 | — |
| Q1 2013 | 2012-09-30 | $1,281 | −$127,558 | −99.01% |
| Q4 2012 | 2012-06-30 | $223,468 | $223,468 | — |
| Q3 2012 | 2012-03-31 | $0 | $0 | — |
| Q2 2012 | 2011-12-31 | $99,090 | $99,090 | — |
| Q1 2012 | 2011-09-30 | $128,839 | $126,813 | +6259.28% |
| Q4 2011 | 2011-06-30 | $0 | — | — |
| Q3 2011 | 2011-03-31 | $0 | — | — |
| Q2 2011 | 2010-12-31 | $0 | — | — |
| Q1 2011 | 2010-09-30 | $2,026 | — | — |
Eloxx Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Eloxx Pharmaceuticals's capital expenditures (capex) decreased from $237,000 to $66,000, a change of −$171,000. The latest reported quarter, Q3 2023, shows $0.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...